Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Rahul K SuryawanshiGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0001-8374-669X
Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0009-0005-2013-8941
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.ORCID 0000-0001-5155-7325
Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-3671-8885
Patrick C O'LearyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-2919-5943
Taha Y TahaGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-7344-7490
Yusuke MatsuiGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-6016-2867
Francisco J Zapatero-BelinchónGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-2751-8411
Maria McCavitt-MalvidoGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0009-0006-4731-6047
Yagmur U DorukHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-3388-7803
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0009-0004-9732-0349
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0001-5900-3060
Manasi P JogalekarHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-1307-4829
Huadong ChenHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-4681-0853
Alicia L RichardsQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.ORCID 0000-0002-4869-2945
Pornparn KongprachaQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.ORCID 0000-0003-1759-213X
Sofia BaliDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-4046-7081
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-0353-0037
Julia RosecransGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0009-0000-3111-5933
Michael MatthayData Science and Biotechnology Institute, Gladstone Institutes, San Francisco, CA.ORCID 0000-0003-3039-8155
Takaya TogoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-0243-0760
Ryan L GonciarzDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-6600-7032
Saumya GopalkrishnanQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.ORCID 0009-0003-6713-4492
R Jeffrey NeitzDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-2247-9345
Nevan J KroganDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-4902-337X
Danielle L SwaneyQuantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA.ORCID 0000-0001-6119-6084
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-6098-7367
Melanie OttGladstone Institute of Virology, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-5697-1274
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-1240-2846
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.ORCID 0000-0003-1446-7878
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-5080-2859
Funding
Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$103.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
SARS-CoV-2 continues to pose a threat to public health. Current therapeutics remain limited to direct acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral lifecycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2. · full record | Socratic